AU2019221837B2 - Agents and methods for treating dysproliferative diseases - Google Patents
Agents and methods for treating dysproliferative diseases Download PDFInfo
- Publication number
- AU2019221837B2 AU2019221837B2 AU2019221837A AU2019221837A AU2019221837B2 AU 2019221837 B2 AU2019221837 B2 AU 2019221837B2 AU 2019221837 A AU2019221837 A AU 2019221837A AU 2019221837 A AU2019221837 A AU 2019221837A AU 2019221837 B2 AU2019221837 B2 AU 2019221837B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- cancer
- meo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
- C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632372P | 2018-02-19 | 2018-02-19 | |
| US62/632,372 | 2018-02-19 | ||
| PCT/US2019/018441 WO2019161345A1 (en) | 2018-02-19 | 2019-02-18 | Agents and methods for treating dysproliferative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019221837A1 AU2019221837A1 (en) | 2020-09-03 |
| AU2019221837B2 true AU2019221837B2 (en) | 2024-08-01 |
Family
ID=67619605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019221837A Expired - Fee Related AU2019221837B2 (en) | 2018-02-19 | 2019-02-18 | Agents and methods for treating dysproliferative diseases |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12215090B2 (https=) |
| EP (1) | EP3755693B1 (https=) |
| JP (1) | JP2021513963A (https=) |
| KR (1) | KR20200123184A (https=) |
| CN (1) | CN112351977A (https=) |
| AU (1) | AU2019221837B2 (https=) |
| CA (1) | CA3091642A1 (https=) |
| IL (1) | IL276639A (https=) |
| WO (1) | WO2019161345A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113149942B (zh) * | 2021-02-10 | 2023-06-02 | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 一种洛克米兰醇酚羟基衍生物、其制备方法和应用 |
| WO2022221519A1 (en) * | 2021-04-14 | 2022-10-20 | Memorial Sloan-Kettering Cancer Center | Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof |
| CN121712777A (zh) * | 2023-08-18 | 2026-03-20 | 皇家学术促进机构麦吉尔大学 | Rna解旋酶抑制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19934952A1 (de) * | 1998-07-30 | 2000-02-03 | Novartis Ag | Cyclopentabenzofuran-Derivate |
| AUPQ866500A0 (en) | 2000-07-05 | 2000-08-03 | Exgenix Operations Pty Ltd | Therapeutic compounds and methods |
| US7816544B2 (en) | 2004-03-23 | 2010-10-19 | Trustees Of Boston University | Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species |
| DE102004024504A1 (de) | 2004-05-18 | 2006-02-16 | Bayer Healthcare Ag | Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung |
| WO2006007634A1 (en) | 2004-07-16 | 2006-01-26 | Cerylid Biosciences Ltd | Processes and intermediates |
| CA2652873A1 (en) | 2006-05-22 | 2007-12-06 | Trustees Of Boston University | Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids |
| US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
| EP2189158A1 (en) | 2008-11-20 | 2010-05-26 | DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts | Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer |
| EP2189453A1 (en) | 2008-11-25 | 2010-05-26 | Université Louis Pasteur | Rocaglaol derivatives as cardioprotectant agents |
| WO2011140334A2 (en) * | 2010-05-06 | 2011-11-10 | Trustees Of Boston University | Compounds, methods of making or identifying compounds, and uses thereof |
| US20140255432A1 (en) | 2011-07-27 | 2014-09-11 | Ohio State Innovation Foundation | Silvestrol, silvestrol analogs and uses thereof |
| WO2013170257A1 (en) | 2012-05-11 | 2013-11-14 | Dana-Farber Cancer Institute, Inc. | Treating muc1-expressing cancers with helicase inhibitors |
| WO2015085221A2 (en) | 2013-12-05 | 2015-06-11 | Memorial Sloan Kettering Cancer Center | Methods for identifying anti-cancer compounds |
| JP6306481B2 (ja) | 2014-03-17 | 2018-04-04 | 株式会社神戸製鋼所 | 延性及び曲げ性に優れた高強度冷延鋼板および高強度溶融亜鉛めっき鋼板、並びにそれらの製造方法 |
| FR3023290B1 (fr) * | 2014-07-04 | 2016-08-19 | Pf Medicament | Derives de flavaglines |
| EP3888658B1 (en) * | 2015-11-25 | 2023-12-27 | Effector Therapeutics, Inc. | Eif4-a-inhibiting compounds and methods related thereto |
| US10639378B2 (en) * | 2016-06-06 | 2020-05-05 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
-
2019
- 2019-02-18 EP EP19753769.9A patent/EP3755693B1/en active Active
- 2019-02-18 AU AU2019221837A patent/AU2019221837B2/en not_active Expired - Fee Related
- 2019-02-18 JP JP2020543209A patent/JP2021513963A/ja active Pending
- 2019-02-18 WO PCT/US2019/018441 patent/WO2019161345A1/en not_active Ceased
- 2019-02-18 KR KR1020207026863A patent/KR20200123184A/ko not_active Ceased
- 2019-02-18 CA CA3091642A patent/CA3091642A1/en active Pending
- 2019-02-18 CN CN201980025251.6A patent/CN112351977A/zh active Pending
- 2019-02-18 US US16/970,918 patent/US12215090B2/en active Active
-
2020
- 2020-08-11 IL IL276639A patent/IL276639A/en unknown
-
2025
- 2025-02-03 US US19/044,242 patent/US20250361218A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200392099A1 (en) | 2020-12-17 |
| US12215090B2 (en) | 2025-02-04 |
| EP3755693A4 (en) | 2021-08-04 |
| IL276639A (en) | 2020-09-30 |
| WO2019161345A1 (en) | 2019-08-22 |
| AU2019221837A1 (en) | 2020-09-03 |
| KR20200123184A (ko) | 2020-10-28 |
| CN112351977A (zh) | 2021-02-09 |
| CA3091642A1 (en) | 2019-08-22 |
| EP3755693A1 (en) | 2020-12-30 |
| JP2021513963A (ja) | 2021-06-03 |
| EP3755693B1 (en) | 2024-06-12 |
| US20250361218A1 (en) | 2025-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250361218A1 (en) | Agents and methods for treating dysproliferative diseases | |
| CN105646389B (zh) | 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途 | |
| JP6787998B2 (ja) | 置換３−（３−アニリノ−１−シクロヘキシル−１ｈ−ベンズイミダゾール−５−イル）プロパン酸誘導体を調製する方法 | |
| KR20010042434A (ko) | 술폰아미드 함유 인돌 화합물 | |
| JP2017520612A (ja) | 抗がん剤としての官能化され置換されたインドール | |
| JP2001504109A (ja) | ベンゾ複素環ジスタマイシン誘導体、それらを製造する方法および抗腫瘍および抗ウイルス剤としてのそれらの用途 | |
| WO2018157842A1 (zh) | 2-(取代苯氨基)苯甲酸类fto抑制剂治疗白血病的用途 | |
| US9902698B2 (en) | 2-[[[2-[(Hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof | |
| CA3093323C (en) | Oxazino-quinazoline and oxazino-quinoline type compound, preparation method and uses thereof | |
| JP2011511803A (ja) | 置換ベンゾオキサゾールのホスファート誘導体 | |
| WO2014020105A1 (fr) | Derives de griseofulvine | |
| KR20250009417A (ko) | 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도 | |
| CN101781268B (zh) | 异噻唑酮取代的苯二羧酸衍生物及其用于制备β-分泌酶抑制剂的用途 | |
| US10093609B2 (en) | TAK1 kinase inhibitors, compositions, and uses related thereto | |
| JPH11209284A (ja) | 骨形成促進剤 | |
| WO1999002527A1 (fr) | Derives de naphthyridine | |
| SK62293A3 (en) | Substituted (benzothiazolyl and quinaxalyl-methoxy) phenyl-acetic acid derivatives | |
| CN117777093A (zh) | 一种用于制备GnRH1R激动剂的小分子化合物 | |
| US20080262010A1 (en) | Crystalline polymorphs of n-(3-(dimethylamino)propyl)-4-(4-(3-fluoro-4-methoxyphenyl) pyrimidin-2-ylamino) benzenesulfonamide as d-glucoronate salts | |
| JPH03163079A (ja) | キサンチン誘導体、それらを有効成分とする気管支拡張剤及び脳機能改善剤 | |
| MXPA99011996A (en) | Bis-indole derivatives having antimetastatic activity, a process for their preparation and pharmaceutical compositions containing them | |
| JP2005298344A (ja) | フェノール誘導体及びその製法 | |
| JPWO1997026242A1 (ja) | ３−（ビス−置換フェニルメチレン）オキシインドール誘導体 | |
| HK1167647B (en) | 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. Free format text: FORMER NAME(S): MEMORIAL SLOAN-KETTERING CANCER CENTER Owner name: MEMORIAL SLOAN-KETTERING CANCER CENTER Free format text: FORMER NAME(S): MEMORIAL SLOAN-KETTERING CANCER CENTER |
|
| MK25 | Application lapsed reg. 22.2i(2) - failure to pay acceptance fee |